U.S. markets open in 4 hours 41 minutes
  • S&P Futures

    4,551.75
    +7.25 (+0.16%)
     
  • Dow Futures

    35,422.00
    +33.00 (+0.09%)
     
  • Nasdaq Futures

    15,641.75
    +54.50 (+0.35%)
     
  • Russell 2000 Futures

    2,255.20
    +5.70 (+0.25%)
     
  • Crude Oil

    82.23
    -0.43 (-0.52%)
     
  • Gold

    1,803.70
    +4.90 (+0.27%)
     
  • Silver

    24.20
    +0.01 (+0.06%)
     
  • EUR/USD

    1.1597
    -0.0009 (-0.08%)
     
  • 10-Yr Bond

    1.5290
    0.0000 (0.00%)
     
  • Vix

    17.06
    +1.08 (+6.76%)
     
  • GBP/USD

    1.3752
    +0.0009 (+0.07%)
     
  • USD/JPY

    113.5920
    -0.2180 (-0.19%)
     
  • BTC-USD

    60,455.65
    +1,452.78 (+2.46%)
     
  • CMC Crypto 200

    1,458.25
    -16.08 (-1.09%)
     
  • FTSE 100

    7,226.18
    -27.09 (-0.37%)
     
  • Nikkei 225

    28,820.09
    -278.15 (-0.96%)
     

CVS Shares Surge On Q3 Earnings, Raised Full-Year Outlook

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Pharmacy benefit manager CVS Health Corporation (NYSE: CVS) beats earnings expectations in the third quarter of 2020. CVS reported $67.06 billion in revenue, which grew 3.5% year-over-year, beating consensus of $66.6 billion. Adjusted diluted earnings per share of $1.66 fell 9.8% YoY, beating consensus of $1.33. Non-GAAP net income declined 9.4% YoY to $2.18 billion.

Key Q3 Highlights: Revenue from the Pharmacy Services segment fell by a marginal 0.9% YoY to $35.71 billion, Retail/LTC segment grew 5.9% YoY to $22.73 billion, and the Healthcare Benefits segment increased 8.8% YoY to $18.70 billion.

CVS generated $12.3 billion in operating cash flow, which grew 20.4% YoY.

The number of Pharmacy claims processed rose by 3.7% YoY to 528.2 million. The retail Prescription volume went up by 5.8% YoY.

Pharmacy Services Generic dispensing rate fell to 87.9% compared to 88.1% in Q3 2019, while the Generic dispensing rate fell to 87.7% from 88.2% last year.

View more earnings on CVS

The number of Medical membership by the end of Q3 fell to 23.3 million, down 0.32 million from Q2, primarily reflecting a decline in Commercial products, partially offset by increases in Medicaid and Medicare products.

FY 2020 Outlook: CVS raised FY 2020 adjusted EPS guidance to range between $7.35 to $7.45, from $7.14 to $7.27 earlier, higher than mean analyst expectations of $7.24.

Operating cash flow guidance raised to range between $12.75 billion to $13.25 billion, from $11.0 billion to $11.5 billion earlier.

Price Action: CVS shares are trading higher by 3.27% to $63.45 in the pre-market session on the last check Friday.

Image Courtesy: Wikimedia

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.